Department of Pathology, Gansu Provincial Hospital, Lanzhou 730000, China.
Department of Occupational Medicine, Third Gansu Provincial Hospital, Lanzhou 730000, China.
Chin Med Sci J. 2023 Jun 30;38(2):130-137. doi: 10.24920/004183.
Objective Primary ovarian small cell carcinoma of pulmonary type (SCCOPT) is a rare ovarian tumor with a poor prognosis. The platinum-based chemotherapy is the standard treatment. However, there is little research on the clinical characteristics of SCCOPT and the potential benefits of other treatments due to its low incidence. The study aims to investigate clinicopathological characteristics and treatment of SCCOPT.Methods We summarized the clinical, imaging, laboratorical and pathological characteristics of 37 SCCOPT cases, in which 6 cases were admitted to the Gansu Provincial Hospital from the year of 2008 to 2022 and 31 cases reported in 17 English and 3 Chinese literatures.Results The median age of the studied SCCOPT cases (=37) was 56.00 (range, 22-80) years. Almost 80% of them had a stage Ⅲ or Ⅳ tumor. All patients underwent an operation and postoperative chemotherapy. Nevertheless, all cases had a poor prognosis, with a median overall survival time of 12 months. Immunohistochemically, the SCCOPT of all patients showed positive expressions of epithelial markers, such as CD56 and sex-determining region of Y chromosome-related high-mobility-group box 2 (SOX-2), and negative expressions of estrogen receptor, progesterone receptor, vimentin, Leu-7, and somatostatin receptor 2. The tumor of above 80% cases expressed synaptophysin. Only a few cases expressed neuron-specific enolase, chromogranin A, and thyroid transcription factor-1. Conclusions SCCOPT had a poor prognosis. SOX-2 could be a biomarker to be used to diagnose SCCOPT.
目的 原发性卵巢小细胞癌肺型（SCCOPT）是一种罕见的卵巢肿瘤，预后较差。铂类化疗是标准治疗方法。然而，由于其发病率低，关于 SCCOPT 的临床特征和其他治疗方法的潜在益处的研究较少。本研究旨在探讨 SCCOPT 的临床病理特征和治疗方法。
方法 我们总结了 37 例 SCCOPT 病例的临床、影像学、实验室和病理学特征，其中 6 例来自 2008 年至 2022 年甘肃省人民医院，31 例来自 17 篇英文文献和 3 篇中文文献。
结果 研究中 SCCOPT 病例的中位年龄（=37）为 56.00 岁（范围 22-80 岁）。几乎 80%的病例为Ⅲ期或Ⅳ期肿瘤。所有患者均接受了手术和术后化疗。然而，所有病例的预后均较差，中位总生存期为 12 个月。免疫组化结果显示，所有患者的 SCCOPT 均表达上皮标志物，如 CD56 和性别决定区 Y 染色体相关高迁移率族盒 2（SOX-2），而雌激素受体、孕激素受体、波形蛋白、Leu-7 和生长抑素受体 2 表达阴性。超过 80%的肿瘤表达突触素。只有少数病例表达神经元特异性烯醇化酶、嗜铬粒蛋白 A 和甲状腺转录因子-1。
结论 SCCOPT 预后较差。SOX-2 可作为诊断 SCCOPT 的标志物。
